Viatris (VTRS) Competitors

Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Is PFE or VTRS a better dividend stock?

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.2%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.8%. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -16.6% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has more risk and volatility, PFE or VTRS?

Pfizer has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Is PFE or VTRS more profitable?

Pfizer has a net margin of 16.84% compared to Viatris' net margin of -24.57%. Pfizer's return on equity of 21.42% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	16.84%	21.42%	9.12%
Viatris	-24.57%	16.54%	7.06%

Which has stronger valuation & earnings, PFE or VTRS?

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.63B	2.15	$8.03B	$1.88	12.78
Viatris	$14.74B	0.78	-$634.20M	-$2.90	-3.41

Do institutionals and insiders believe in PFE or VTRS?

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.1% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media refer more to PFE or VTRS?

In the previous week, Pfizer had 66 more articles in the media than Viatris. MarketBeat recorded 70 mentions for Pfizer and 4 mentions for Viatris. Pfizer's average media sentiment score of 1.30 beat Viatris' score of -0.40 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	57 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate PFE or VTRS?

Pfizer currently has a consensus target price of $28.12, indicating a potential upside of 17.01%. Viatris has a consensus target price of $10.40, indicating a potential upside of 5.05%. Given Pfizer's stronger consensus rating and higher possible upside, research analysts plainly believe Pfizer is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.39
Viatris	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Pfizer beats Viatris on 16 of the 20 factors compared between the two stocks.